Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Couple of studies

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 03, 2022 5:23pm

196 Views

Post# 34798249

RE:Couple of studies

Because it was EASL a week or two ago there's been quite a bit of news around NASH. Novo Nordisk clarified their approach. While looking into what they had I ended up on their pipeline. They have a GH secretalogue which they are developing for GHD diagnosis but which essentially does the same thing as Egrifta. It works on a different receptor but still stimulates endogenous GH production. It got me thinking that maybe the weakness in THTX IP might be the presence of these other GH stimulators (including oral drugs) which could do the same job as Egrifta. The THTX patent makes a couple of general references to GH secretalogues but the bulk is specifically around the GHRH sequence and variants of it. I've started to wonder whether this is the weakness in the NASH program.

scarlet1967 wrote:

GH/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight/obesity

“Higher peak-stimulated GH was also associated with lower ALT. Higher IGF-1 was associated with lower risk of liver fibrosis by Fibrosis-4 scores.

Individuals with NAFLD have lower peak-stimulated GH but similar IGF-1 levels versus controls. Higher peak-stimulated GH is associated with lower IHL and less hepatocellular damage. Higher IGF-1 is associated with more favorable fibrosis risk scores. These data implicate GH and IGF-1 as potential disease modifiers in the development and progression of NAFLD.”

So there are concluding higher IGF-1 levels will result in lower fibrosis by fibrosis-4 score.

https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciac337/6577095?redirectedFrom=PDF

The FibroScan–aspartate aminotransferase (FAST) score was developed to identify patients who have histologic NASH with high nonalcoholic fatty liver disease activity score (NAS ≥4) and significant liver fibrosis (≥F2), which has been associated with higher risk of end-stage liver disease.

“On multivariable analysis, HIV infection was associated with 3.7-fold higher odds of elevated FAST score (P = .002), and greater waist circumference (per 10cm) was associated with 1.7-fold higher odds (P < .001).

Our findings suggest that HIV is an independent risk factor for NASH with significant activity and fibrosis.”

Again HIV seems to increase not only NAS score but also the fibrosis and we know Tesamorelin was only tried in PLWH.

I have sent both studies to Christian. I don’t have access to the full articles!